

(10) International Publication Number
WO 2014/040056 A1(43) International Publication Date
13 March 2014 (13.03.2014)

(51) International Patent Classification:

C07J 63/00 (2006.01) A61P 29/00 (2006.01)
A61K 31/56 (2006.01)

(21) International Application Number:

PCT/US2013/059015

(22) International Filing Date:

10 September 2013 (10.09.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/699,199 10 September 2012 (10.09.2012) US

(71) Applicant: REATA PHARMACEUTICALS, INC.
[US/US]; 2801 Gateway Drive, Suite 150, Irving, TX
75063-2648 (US).(72) Inventors: JIANG, Xin; c/o 2801 Gateway Drive, Suite
150, Irving, TX 75063-2648 (US). BENDER, Christoph-
er, F.; c/o 2801 Gateway Drive, Suite 150, Irving, TX
75063-2648 (US). VISNICK, Melean; c/o 2801 Gateway
Drive, Suite 150, Irving, TX 75063-2648 (US).(74) Agent: VOGES, Mark, H.; Parker Highlander PLLC,
1120 S. Capital of Texas Highway, Building One, Suite
200, Austin, TX 78746 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF



(I)

(57) Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula (I): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as anti-oxidant inflammation modulators, and compositions thereof are also provided.